Acta Pharmacologica Sinica

Contents

Monthly 2024 June; 45 (6)

Acta Pharmacologica Sinica

Contents

Monthly 2024 June; 45 (6)

Cover

In this cover article, Zhou et al. constructed a novel mechanistic quantitative systems pharmacology model describing the underlying pathophysiological processes of HER2$^+$ BC, from ligand-receptor binding to downstream signaling and finally to tumor growth, while incorporating the distinct modalities and mechanisms of various state-of-the-art therapeutics. A large variety of in vitro and in vivo experimental data was used during model calibration and validation, achieving a quantitative and accurate description of cellular signaling, time-response, dose-response, and tumor growth kinetics. In a high-throughput manner, this multiscale QSP model platform enabled researchers to probe into the efficacy of different therapeutic strategies at the preclinical level, generate new hypothesis regarding best treatment combinations to overcome resistance, and suggested important directions for future translational drug research and model-informed drug development. See the article in pages 1287–1304.

EXECUTIVE EDITOR FOR THIS ISSUE XU, Jia (Shanghai)

ACTA PHARMACOLOGICA SINICA (Monthly)
2024 June; Volume 45 Number 6
(Founded in September, 1980)

Sponsored by
Chinese Pharmacological Society
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Supervised by
China Association for Science and Technology
Editor-in-chief
DING, Jian
Edited by
Editorial Board of Acta Pharmacologica Sinica
294 Tai-yuan Road, Shanghai 200031, China
Http://www.chinaphar.com
E-mail aps@simm.ac.cn
Phn 86-21-5492-2821, 5492-2822; Fax 86-21-5492-2823

Published jointly by
Editorial Office of Acta Pharmacologica Sinica
Springer Nature
Publication date
5th every month
Printed by
Shanghai Shengtong Times Printing Co Ltd
568 Guang-ye Road, Shanghai 201506, China

《中国药理学报》编辑部出版
国内统一连续出版物号
CN 31-1347/R

国内外公开发行
国内邮发代号 4-295
国内每期 200.00 元